Edition:
United States

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

11.53EUR
24 Mar 2017
Change (% chg)

€0.04 (+0.35%)
Prev Close
€11.49
Open
€11.81
Day's High
€12.29
Day's Low
€11.40
Volume
380,975
Avg. Vol
215,635
52-wk High
€15.24
52-wk Low
€5.65

Latest Key Developments (Source: Significant Developments)

Medigene revises collaboration with Mitsui Norin
Thursday, 23 Mar 2017 09:15am EDT 

Medigene AG : Medigene revises collaboration with Mitsui Norin . Today announced a new contractual arrangement with Mitsui Norin Co. Ltd, regarding its drug Veregen . Current manufacturing and supply agreement has been mutually terminated as of March 31, 2017 . Previous agreement has been replaced by a new license agreement covering drug master file (DMF) for Veregen . As a part of arrangement to terminate existing manufacturing and supply agreement, Medigene has agreed to a one-time payment of $1.75 million to Mitsui Norin . Additional payment to Mitsui Norin for up to $0.5 million to reimburse costs of ending production is also expected in course of 2017 .No further financial details regarding new license agreement were disclosed.  Full Article

Medigene FY total revenue increases 43 pct to 9.8 mln euros
Thursday, 23 Mar 2017 02:30am EDT 

Medigene Ag : FY total revenue increases 43 pct to 9.8 million euros ($10.58 million) . Financial guidance for 2016 met . Financial guidance for 2017 reflects Medigene's alignment and continued focus on its core business of immunotherapies . 2017 revenue: planned total revenue in 2017 between 8 - 10 million euros . 2017 projected EBITDA loss of 16 - 18 million euros . For 2017 Medigene anticipates cash utilization of between 23 - 27 million euros, partly due to non-recurring effects such as investments in laboratory infrastructure . FY net loss for year was reduced by 27 pct to 9.492 million euros (2015: 12.999 million euros) .Company has sufficient financial resources to fund business operations well beyond forecast horizon of two years.  Full Article

bluebird bio and Medigene establish strategic T cell receptor alliance
Thursday, 29 Sep 2016 02:09am EDT 

Medigene AG : bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy . Medigene will be responsible for generation and delivery of TCRs using its TCR isolation and characterization platform . Medigene will receive an upfront payment of $15 million .Medigene will receive research and development funding for all work performed in the collaboration and is eligible for tiered royalty payments on net sales up to a double-digit percentage.  Full Article

Medigene H1 total revenue up 62 pct at 5.5 mln euros
Friday, 5 Aug 2016 01:38am EDT 

Medigene AG : H1 total revenue increased by 62 pct to 5.470 million euros (6M 2015: 3.372 million euros) . H1 cash and cash equivalents and time deposits increased by 4 pct to 48.672 million euros (12/31/2015: 46.759 million euros) . Confirms its financial guidance for fiscal year 2016 . H1 research and development expenses increased by 23 pct to 5.079 million euros (6M 2015: 4.117 million euros) .H1 EBITDA loss reduced by 6 pct to 4.011 million euros (6M 2015: 4.251 million euros).  Full Article

Medigene: grant of US patent for method for identification of CD4+ t cell antigens
Monday, 25 Jul 2016 01:30am EDT 

Medigene AG : Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens . Patent covers a rapid and efficient method for identifying tumor-specific antigens .Expected to facilitate use of neoantigens in personalized T-cell therapies.  Full Article

Medigene joins Max Delbrück Centre and Charité for first clinical TCR study in Germany
Wednesday, 29 Jun 2016 01:30am EDT 

Medigene AG :Enters into a cooperation agreement with Max Delbrück Centre for Molecular Medicine in Helmholtz Association (MDC) and the Charité - Universitätsmedizin Berlin (Charité).  Full Article

Medigene commissions EUFETS for cell production process for first own TCR studies
Wednesday, 18 May 2016 01:30am EDT 

Medigene AG : Commissions EUFETS for cell production process for first own TCR studies .EUFETS will set up cell production together with Medigene for supplying company's planned phase I/II TCR studies.  Full Article

Medigene Q1 total revenue up at 3.909 mln euros
Thursday, 12 May 2016 01:31am EDT 

Medigene AG : Q1 increase in total revenue by 132 pct to 3.909 million euros (3m 2015: 1.686 mln euros) . Q1 EBITDA loss reduced by 54 pct to 939,000 euros (3m 2015: 2.042 million euros) . Q1 increase in research and development expenses for immunotherapies by 64 pct to 1.907 million euros (3m 2015: 1.166 mln euros) .Confirmation of financial guidance 2016.  Full Article

Medigene announces issuance and number of new shares
Tuesday, 10 May 2016 10:41am EDT 

Medigene AG : Medigene announces issuance and number of new shares to settle milestone payment for start of phase II trial with dc vaccines . Milestone payment in value of approx 3.2 million euros ($3.65 million) announced on April 1 will be settled through issuance of 392,875 new shares from authorized capital as part of capital increase through contributions in kind .Thereby, company will increase its share capital of 19,688,960.00 euros up to 20,081,835.00 euros.  Full Article

Medigene sells partial stake in Immunocore
Monday, 4 Apr 2016 11:59am EDT 

Medigene AG:Sells partial stake in Immunocore.Sold 50 pct of its' stake in private biotech company Immunocore Ltd., UK, for approximately 4.9 million pounds (about 6.1 million euros).  Full Article

More From Around the Web

BRIEF-Medigene revises collaboration with Mitsui Norin

* Today announced a new contractual arrangement with Mitsui Norin Co. Ltd, regarding its drug Veregen